



## Drug Coverage Policy

Effective Date.....11/21/2024

Coverage Policy Number.....IP0185

Policy Title..... Zolgensma

# Spinal Muscular Atrophy – Gene Therapy – Zolgensma

- Zolgensma® (onasemnogene abeparvovec-xioi intravenous infusion – Novartis)

### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## Cigna Healthcare Coverage Policy

### OVERVIEW

Zolgensma, an adeno-associated virus vector-based gene therapy, is indicated for the treatment of spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene in patients who are less than 2 years of age.<sup>1</sup>

Limitations of use are that the safety and effectiveness of repeat administration of Zolgensma have not been evaluated.<sup>1</sup> The use of Zolgensma in patients with advanced spinal muscular atrophy (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been assessed. Use

of Zolgensma in premature neonates before reaching full-term gestational age is not recommended because concomitant treatment with corticosteroids may adversely affect neurological development. Zolgensma therapy should be delayed until full-term gestational age is achieved. The definition of full-term pregnancy commences at 39 weeks and 0 days gestation.<sup>2</sup>

### Disease Overview

Spinal muscular atrophy is a genetic, autosomal recessive muscular disorder caused by deletion or loss of function mutation in the SMN1 gene.<sup>3-6</sup> The reduced levels of survival motor neuron (SMN) protein causes degeneration of lower motor neurons. The phenotypic expression of the disease is impacted by the survival motor neuron 2 (SMN2) gene copy number. Data have shown that patients with a higher number of SMN2 gene copies generally have a more mild phenotypic disease expression. Gene deletion testing for spinal muscular atrophy can be performed at many diagnostic laboratories. Table 1 describes disease types. Of note, various motor ability assessments are used in clinical practice to characterize functional impairment in spinal muscular atrophy. Different function motor scales are utilized to evaluate patients. When motor neuron function is lost, it cannot be regained, which greatly impacts patients who have experienced progression (e.g., patients with complete paralysis of limbs or permanent ventilator dependence).

**Table 1. Types of Spinal Muscular Atrophy.<sup>5</sup>**

	Age at Onset	Features/Clinical Presentation*	Lifespan*	SMN2 Gene Copy Number
Type 0 (< 1% of patients)	Birth	Severe hypotonia and weakness; respiratory failure at birth. There is no achievement of motor milestones. Patients will never be able to sit.	< 6 months	1
Type 1 (50% to 60% of patients)	< 6 months	Poor muscle tone, lack of movement, and respiratory assistance is needed. Patients are never able to sit.	< 2 years	1 to 2 for 80% of patients
Type 2 (30% of patients)	7 to 18 months	Patients are able to sit. However, patients are unable to walk or stand without assistance.	Close to normal	2 to 3 for 90% of patients
Type 3 (10% of patients)	18 months to 30 years	Walks independently but may lose this ability as the disease progresses.	Close to normal	3 to 5 for most patients
Type 4 (< 1% of patients)	> 18 years	Walk until adulthood.	Normal	4 for 75% of patients; 5 or 6 for 25% of patients

\* Without disease-modifying treatment or mechanical ventilation; SMN2 – Survival motor neuron 2.

Besides Zolgensma, other therapies are available. **Spinraza**® (nusinersen intrathecal injection), a SMN2-directed antisense oligonucleotide, is indicated for the treatment of spinal muscular atrophy in pediatric and adult patients.<sup>7</sup> Spinraza is given by intrathecal injection. Although studies and experience continue, the primary pivotal data include infantile-onset (Type 1) and later-onset (Type 2 and Type 3) spinal muscular atrophy primarily in children. Data are also available with Spinraza in presymptomatic infants who were genetically diagnosed with spinal muscular atrophy. There are some data with Spinraza in adults as well.

**Evrysdi**® (risdiplam oral solution), a SMN2 splicing modifier, is indicated for the treatment of spinal muscular atrophy in pediatric and adult patients.<sup>8</sup> The primary pivotal data include infantile-onset (Type 1) and later-onset (Type 2 and Type 3) spinal muscular atrophy, primarily in children and

adults up to 25 years of age. Other information is available in older adults. Data are also available in presymptomatic infants who were genetically diagnosed with spinal muscular atrophy.

### **Clinical Efficacy**

The efficacy of Zolgensma was evaluated in patients less than 2 years of age with spinal muscular atrophy who had bi-allelic mutations in the SMN1 gene.<sup>1,9-14</sup> One trial was an open-label, single-arm study which is ongoing (STRIVE [n = 21])<sup>11</sup> and the other was an open-label, single-arm, ascending-dose clinical trial (START [n = 15] {12 patients received a therapeutic dose}).<sup>1,9,10</sup> Symptoms onset occurred before patients were 6 months of age. All patients had genetically confirmed bi-allelic SMN1 gene deletions and two SMN2 gene copies. In both trials, Zolgensma was given as a single-dose intravenous infusion. Efficacy was assessed on parameters such as survival and achievement of developmental motor milestones (e.g., sitting without support, standing without assistance). The definition of survival was the time from birth to either death or permanent ventilation. Other efficacy parameters were evaluated (e.g., assessment of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores, ventilator use). In general, patients who received Zolgensma experienced better outcomes compared with what would normally be anticipated without treatment. Other data are also available regarding Zolgensma.<sup>10-15</sup>

### **Guidelines**

The Spinal Muscular Atrophy Newborn Screening Multidisciplinary Working Group is comprised of clinicians and geneticists with expertise in spinal muscular atrophy who developed a treatment algorithm in 2018 for infants who have positive results from a newborn screening test for spinal muscular atrophy.<sup>16</sup> Spinal muscular atrophy Types 1 and 2 comprise a large majority of cases and account for many patients who screen positively for spinal muscular atrophy with three or fewer SMN2 gene copies. Immediate treatment is recommended in patients with two or three SMN2 gene copies. Treatment recommendations for patients who screen positive for spinal muscular atrophy and have only one SMN2 gene copy are more complicated. It is likely that patients with only one SMN2 gene copy will likely be symptomatic at birth and the physician should determine if treatment is warranted.<sup>16</sup> In 2020, the Working Group updated recommendations that infants diagnosed with spinal muscular atrophy via newborn screening with four SMN2 gene copies should receive immediate treatment.<sup>17</sup> Also, patients with five (or more) SMN2 gene copies should be observed and screened for symptoms.

### **Dosing**

The recommended dose of Zolgensma is  $1.1 \times 10^{14}$  vector genomes (vg) per kg of body weight.<sup>1</sup> Administer Zolgensma as an intravenous infusion over 60 minutes. Starting 1 day prior to Zolgensma infusion, give systemic corticosteroids equivalent to oral prednisolone 1 mg/kg of body weight for a total of 30 days. Examine liver function after this juncture and follow recommended guidelines.

### **Safety**

Zolgensma has a Boxed Warning regarding acute serious liver injury and acute liver failure.<sup>1</sup> Elevated aminotransferases can occur with Zolgensma. Patients with preexisting liver impairment may be at higher risk. Prior to infusion, evaluate liver function in all patients by clinical examination and laboratory testing. One day before Zolgensma infusion, commence administration of systemic corticosteroids equivalent to oral prednisolone at 1 mg/kg of body weight per day for a total of 30 days. Prior to administration of Zolgensma, evaluate creatinine and complete blood counts. Perform baseline anti-AAV9 antibody testing prior to Zolgensma infusion. Patients in the Zolgensma trials were required to have baseline anti-AAV9 antibody titers of  $\leq 1:50$ .

## **Medical Necessity Criteria**

## POLICY STATEMENT

Prior Authorization is recommended for benefit coverage of Zolgensma. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Because of the specialized skills required for evaluation and diagnosis of patients treated with Zolgensma as well as the specialized training required for administration of Zolgensma, approval requires Zolgensma to be prescribed by a physician who has consulted with or who specializes in the condition. All approvals are provided for one-time (per lifetime) as a single dose. The approval duration is 1 month to allow for an adequate timeframe to prepare and administer one dose of therapy. For the dosing criteria, verification of the appropriate weight-based dosing is required by a Medical Director as noted by **[verification required]**. If claims history is available, verification is required for certain criteria as noted by **[verification in claims history required]**. All reviews (approvals and denials) will be forwarded to the Medical Director for evaluation.

**Documentation:** Documentation is required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to chart notes, laboratory results, medical test results, claims records, prescription receipts, and/or other information.

**Zolgensma is considered medically necessary when the following criteria are met:**

### FDA-Approved Indication

- 1. Spinal Muscular Atrophy – Treatment.** Approve for a one-time (per lifetime) single dose if the patient meets ALL of the following (A, B, C, D, E, F, G, H, I, J, K, L, M, N, and O):
  - A)** Patient is less than 2 years of age; AND
  - B)** If the patient is a premature neonate, full-term gestation age of 39 weeks and 0 days has been met; AND  
Note: Full-term gestational age can be defined as the postmenstrual age (gestational age plus chronological age) being equal to  $\geq$  39 weeks and 0 days.
  - C)** Patient has not received Zolgensma in the past **[verification in claims history required]**; AND  
Note: If no claim for Zolgensma is present (or if claims history is not available), the prescribing physician confirms that the patient has not previously received Zolgensma.
  - D)** Patient has had a genetic test confirming the diagnosis of spinal muscular atrophy with bi-allelic pathogenic variants in the survival motor neuron 1 (SMN1) gene **[documentation required]**; AND  
Note: Pathogenic variants may include homozygous deletion, compound heterozygous mutation, or a variety of other rare mutations.
  - E)** Patient meets ONE of the following (i or ii):
    - i.** Patient has three or fewer survival motor neuron 2 (SMN2) gene copies **[documentation required]**; OR
    - ii.** Patient meets BOTH of the following (a and b):
      - a)** Patient has four SMN2 gene copies **[documentation required]**; AND
      - b)** The number of SMN2 gene copies has been determined by a quantitative assay capable of distinguishing between four SMN2 gene copies and five or greater SMN2 gene copies; AND
  - F)** According to the prescribing physician, patient has started or will receive systemic corticosteroids equivalent to oral prednisolone at a dose of 1 mg/kg per day commencing 1 day prior to Zolgensma infusion and for a total of 30 days; AND
  - G)** Baseline anti-AAV9 antibody titers are  $\leq$  1:50 **[documentation required]**; AND
  - H)** Patient has undergone liver function testing within the past 30 days and meets ALL of the following (i, ii, iii, and iv):
    - i.** Alanine aminotransferase levels are  $\leq$  2 times the upper limit of normal **[documentation required]**; AND

- ii. Aspartate aminotransferase levels are  $\leq 2$  times the upper limit of normal **[documentation required]**; AND
- iii. Total bilirubin levels are  $\leq 2$  times the upper limit of normal **[documentation required]**; AND  
 Note: Patient with elevated bilirubin levels due to neonatal jaundice are acceptable.
- iv. Prothrombin time results are  $\leq 2$  times the upper limit of normal **[documentation required]**; AND
- I) Patient has undergone a renal function assessment within the past 30 days and has a creatinine level  $< 1.0$  mg/dL **[documentation required]**; AND
- J) A complete blood count has been obtained within the past 30 days and the patient meets BOTH of the following (i and ii):
  - i. White blood cell count is  $\leq 20,000$  cells per  $\text{mm}^3$  **[documentation required]**; AND
  - ii. Hemoglobin levels are between 8 g/dL and 18 g/dL **[documentation required]**; AND
- K) For a patient currently receiving or who has received prior treatment with Spinraza (nusinersen intrathecal injection), the prescribing physician confirms that further therapy with Spinraza will be discontinued; AND
- L) For a patient currently receiving or who has received prior treatment with Evrysdi (risdiplam oral solution), the prescribing physician confirms that further therapy with Evrysdi will be discontinued; AND
- M) Medication is prescribed by a physician who has consulted with or who specializes in the management of patients with spinal muscular atrophy and/or neuromuscular disorders; AND
- N) Current patient body weight has been obtained within the past 14 days **[documentation required]**; AND
- O) If criteria A through N are met, approve one dose of Zolgensma to provide for a one-time (per lifetime) single dose of  $1.1 \times 10^{14}$  vector genomes per kg (vg/kg) of body weight by intravenous infusion **[verification required]**. Zolgensma is provided as a customized kit to meet dosing requirements for each patient per their weight (in kilograms). Zolgensma kit sizes (per the cited NDC) are in Table 2.

**Dosing.** The recommended dose of Zolgensma is one-time (per lifetime) as a single-dose intravenous infusion of  $1.1 \times 10^{14}$  vector genomes (vg)/kg based on the current patient weight in kg (within the past 14 days). Zolgensma is provided as a customized kit to meet dosing requirements for each patient per their weight (in kilograms). Refer to the appropriate NDC number below for approval.

**Table 2. Zolgensma Kit Sizes.<sup>1</sup>**

Patient Weight Range (kg)	Zolgensma Kit Sizes			NDC Number
	5.5 mL vial <sup>+</sup>	8.3 mL vial <sup>o</sup>	Total Vials per Kit	
2.6 to 3.0	0	2	2	71894-120-02
3.1 to 3.5	2	1	3	71894-121-03
3.6 to 4.0	1	2	3	71894-122-03
4.1 to 4.5	0	3	3	71894-123-03
4.6 to 5.0	2	2	4	71894-124-04
5.1. to 5.5	1	3	4	71894-125-04
5.6 to 6.0	0	4	4	71894-126-04
6.1 to 6.5	2	3	5	71894-127-05
6.6 to 7.0	1	4	5	71894-128-05
7.1 to 7.5	0	5	5	71894-129-05
7.6 to 8.0	2	4	6	71894-130-06
8.1 to 8.5	1	5	6	71894-131-06
8.6 to 9.0	0	6	6	71894-132-06

**Table 2 (continued). Zolgensma Kit Sizes.<sup>1</sup>**

Patient Weight Range (kg)	Zolgensma Kit Sizes			NDC Number
	5.5 mL vial <sup>†</sup>	8.3 mL vial <sup>°</sup>	Total Vials per Kit	
9.1 to 9.5	2	5	7	71894-133-07
9.6 to 10.0	1	6	7	71894-134-07
10.1 to 10.5	0	7	7	71894-135-07
10.6 to 11.0	2	6	8	71894-136-08
11.1 to 11.5	1	7	8	71894-137-08
11.6 to 12.0	0	8	8	71894-138-08
12.1 to 12.5	2	7	9	71894-139-09
12.6 to 13.0	1	8	9	71894-140-09
13.1 to 13.5	0	9	9	71894-141-09
13.6 to 14.0	2	8	10	71894-142-10
14.1 to 14.5	1	9	10	71894-143-10
14.6 to 15.0	0	10	10	71894-144-10
15.1 to 15.5	2	9	11	71894-145-11
15.6 to 16.0	1	10	11	71894-146-11
16.1 to 16.5	0	11	11	71894-147-11
16.6 to 17.0	2	10	12	71894-148-12
17.1 to 17.5	1	11	12	71894-149-12
17.6 to 18.0	0	12	12	71894-150-12
18.1 to 18.5	2	11	13	71894-151-13
18.6 to 19.0	1	12	13	71894-152-13
19.1 to 19.5	0	13	13	71894-153-13
19.6 to 20.0	2	12	14	71894-154-14
20.1 to 20.5	1	13	14	71894-155-14
20.6 to 21.0	0	14	14	71894-156-14

<sup>†</sup> Vial nominal concentration is  $2.0 \times 10^{13}$  vg/mL and contains an extractable volume of not less than 5.5 mL; <sup>°</sup> Vial nominal concentration is  $2.0 \times 10^{13}$  vg/mL and contains an extractable volume of not less than 8.3 mL.

## Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Patient has Complete Paralysis of All Limbs.** This is cited as a limitation of use in the Zolgensma prescribing information.<sup>1</sup> Data are needed to determine if this patient population would derive benefits from Zolgensma.
- 2. Patient has Permanent Ventilator Dependence.** This is cited as a limitation of use in the Zolgensma prescribing information.<sup>1</sup> Data are needed to determine if this patient population would derive benefits from Zolgensma.
- 3. Administration in Individuals in Utero.** Zolgensma is not approved for in utero administration per the prescribing information.
- 4. Prior Receipt of Gene Therapy.** Zolgensma has not been studied in patients who previously received gene therapy.

## Coding Information

**Note:** 1) This list of codes may not be all-inclusive.  
 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPCS Codes	Description
J3399	Injection, onasemnogene abeparvovec-xioi, per treatment, up to $5 \times 10^{15}$ vector genomes

## References

1. Zolgensma® intravenous infusion [prescribing information]. Bannockburn, IL: Novartis; July 2024.
2. ACOG Committee Opinion No 579: Definition of term pregnancy. *Obstet Gynecol.* 2013;122(5):1139-1140.
3. Schroth M, Deans J, Arya K, et al. Spinal muscular atrophy update in best practices. Recommendations for diagnosis considerations. *Neurology.* 2024;14:e200310.
4. Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. *Lancet Neurol.* 2024;23:205-218.
5. Ramdas S, Oskoui M, Servais L. Treatment options in spinal muscular atrophy: a pragmatic approach for clinicians. *Drugs.* 2024;84:747-762.
6. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated 2024 September 19]. In: Adam MP, Feldman J, Mirzaa GM, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available at: [https://www.ncbi.nlm.nih.gov/books/NBK1352/pdf/Bookshelf\\_NBK1352.pdf](https://www.ncbi.nlm.nih.gov/books/NBK1352/pdf/Bookshelf_NBK1352.pdf). Accessed on September 26, 2024.
7. Spinraza® intrathecal injection [prescribing information]. Cambridge, MA: Biogen; April 2024.
8. Evrysdi® oral solution [prescribing information]. South San Francisco, CA: Genentech/Roche; October 2023.
9. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene replacement therapy for spinal muscular atrophy. *N Engl J Med.* 2017;377(18):1713-1722.
10. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the Phase I START trial of onasemnogene abeparvovec in spinal muscular atrophy. *JAMA Neurol.* 2021;78(7):834-841.
11. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset muscular atrophy in patients with two copies of SMN2 (STRIVE): an open-label, single-arm, multicenter, phase 3 trial. *Lancet Neurol.* 2021;20:284-293.
12. Strauss KA, Farrar MS, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. *Nat Med.* 2022;28:1390-1397.
13. Strauss KA, Farrar MS, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. *Nat Med.* 2022;28:1381-1389.
14. Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 2 (STRIVE-EU): an open-label, single-arm, multicenter, phase 3 trial. *Lancet Neurol.* 2021;20:832-841.
15. Blair HA. Onasemnogene abeparvovec: a review of spinal muscular atrophy. *CNS Drugs.* 2022;36:995-1005.



16. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. *J Neuromuscul Dis.* 2018;5:145-158.
17. Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. *J Neuromuscul Dis.* 2020;7(2):97-100.

## Revision Details

Type of Revision	Summary of Changes	Date
Annual Revision	<p><b>Added</b> "Policy Statement" to the policy.</p> <p><b>Added "Documentation:</b> Documentation is required where noted in the criteria as <b>[documentation required]</b>. Documentation may include, but is not limited to chart notes, laboratory results, medical test results, claims records, prescription receipts, and/or other information."</p> <p><b>Spinal Muscular Atrophy – Treatment:</b></p> <ul style="list-style-type: none"> <li>• <b>Updated</b> criterion <b>from</b> "If premature neonate, full-term gestational age has been met" to "If the patient is a premature neonate, full-term gestation age of 39 weeks and 0 days has been met" and <b>added</b> "<u>Note:</u> Full-term gestational age can be defined as the postmenstrual age (gestational age plus chronological age) being equal to <math>\geq</math> 39 weeks and 0 days."</li> <li>• <b>Added</b> "<u>Note:</u> Pathogenic variants may include homozygous deletion, compound heterozygous mutation, or a variety of other rare mutations" to the criteria "Patient has had a genetic test confirming the diagnosis of spinal muscular atrophy with bi-allelic pathogenic variants in the survival motor neuron 1 (SMN1) gene."</li> <li>• <b>Updated</b> criterion <b>from</b> "No previous use of onasemnogene abeparvovec-xioi (Zolgensma)" <b>to</b> "Patient has <u>not</u> received Zolgensma in the past <b>[verification in claims history required]</b>" and <b>added</b> "<u>Note:</u> If no claim for Zolgensma is present (or if claims history is not available), the prescribing physician confirms that the patient has <u>not</u> previously received Zolgensma."</li> <li>• <b>Updated</b> criterion <b>from</b> "Prescriber attests that prophylactic systemic corticosteroids, equivalent to oral prednisolone at a dose of 1 mg/kg per day, will commence 1 day prior to Zolgensma infusion and will continue daily for a total of 30 days" <b>to</b> "According to the prescribing physician, patient has started or will receive systemic corticosteroids equivalent to oral prednisolone at a dose of 1 mg/kg per day commencing 1 day</li> </ul>	11/21/2024



	<p>prior to Zolgensma infusion and for a total of 30 days.”</p> <ul style="list-style-type: none"> <li>• The phrase “liver function assessment” was replaced with “liver function testing.”</li> <li>• In phrases in which a requirement is “within the last 30 days”, the word “last” was replaced with “past”.</li> <li>• <b>Added</b> criterion “Current patient body weight has been obtained within the past 14 days [documentation required].”</li> <li>• <b>Added</b> criterion “If criteria A through N are met, approve one dose of Zolgensma to provide for a one-time (per lifetime) single dose of 1.1 x 10<sup>14</sup> vector genomes per kg (vg/kg) of body weight by intravenous infusion [verification required]. Zolgensma is provided as a customized kit to meet dosing requirements for each patient per their weight (in kilograms). Zolgensma kit sizes (per the cited NDC) are in Table 2.”</li> </ul> <p><b>Authorization Duration:</b>  <b>Updated from</b> “Authorization is for a one-time treatment for a one month duration or until 2 years of age, whichever comes first” to “Approve for a one-time (per lifetime) single dose if the patient meets ALL of the following;”</p> <p><b>Conditions Not Recommended for Approval:</b>  The conditions of “Prior Receipt of Gene Therapy” and “Administration in Individuals in Utero” were added.</p>	
--	--	--

The policy effective date is in force until updated or retired.

---

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.